One of the main disadvantages of clinical trials is their time-consuming nature. Results publication can take years which is problematic for some reasons.

However, there are different ways to improve the speed of decentralized clinical trials (DCTs). We must ask objective questions such as the future of clinical trials and what it looks like. The responses to these questions are the basis of this article.

The Power of AI in Transforming Clinical Trials

Artificial Intelligence (AI) in clinical trials relies on human behaviour to influence drug trial processes and procedures. It helps zero down to the sample population, clinical trial, and drug administration.

Before AI, trials took a long time to test, which led to delays in actualisation. Time directly affects resources, both human and capital, and can affect the whole process.

As technology settles in, we can carry out multiple clinical trials spread over a large area. Healthcare data is used to sample the population, while geo-mapping creates clinical trial locations.

The outcome shows significant improvement in the clinical trial process, especially in data collection, simultaneous trials and faster project execution. With pandemics such as coronavirus ravaging the world, AI is the only way pharmaceutical companies can speed up vaccine testing and administration.

Technology and Medicine; Why AI is the Future of Clinical Trials

• AI influences the drug production rate.
• Data generated from the trails is first-hand and accurate, which leads to better inference.
• Clinical trial processes improve since pharmaceutical companies can easily update their processes for a better outcome.

Decentralised and Hybrid Clinical Trials

Decentralised clinical trials involve remote trials and administration of clinical trials directly to the sample population. It mostly involves mobile devices with specialised applications where the trial participants record their findings. The system then collates the data and helps the researcher infer.

Hybrid trials mix the centralised and decentralised methods. Data collection comes in through the trial participants and the research assistants.

It works well when the clinical trials need professional observation, which can affect the effectiveness of the trials. Compared to the centralised or decentralised method, the hybrid method brings in enriched data, factoring in all factors and conditions.

Clinical trials for ailments such as cancer and other terminal ailments benefit more from the hybrid clinical trials.

Why Decentralisation is the Future of Clinical Trails

• Advancement in medical research and development warrants attention to detail. Hybrid clinical trials offer precision and speed in drug development.
• Language barrier, real-world data and clinical research deliveries are assured in record time and efficiency.
• In hybrid clinical trials, trial participant convertibility is high since the researcher is available to assist them in understanding the process and its benefits in the medical field.

The Future of Clinical Trials

Many people are yet to embrace clinical trials due to fear of infection and mortality. However, the balance is slowly tilting, giving pharmaceutical companies more trial participants. Technology helps in sampling participants to improve the intake.

Even with the notable strides, we still have to deal with factors such as controlled movements in quarantines, limited personnel and reliance on the patient’s memory. In some instances, the research team has to rely on outdated data.

In essence, the success of a clinical trial significantly relies on data patients/trial participants generated over time. It forms the basis from which the sample population emanates and has a direct relationship with the drugs produced.

To improve the whole process, pharmaceuticals and drug research organisations should invest in a survey tool that brings out the desirable properties. It should help narrow down the sample population, gather data from the field and help narrow down to the desired drug.

Despite the game-changing features of AI and technology, you need professionals to chaperone the process. They bring in human intervention and interpretation, which aligns clinical trials on the goal.

Coronavirus is a perfect study in this case. It was infectious and widespread, but a combination of decentralised and hybrid clinical trials resulted in vaccine production. It is one of the fastest pandemic interventions in pharmaceutical technology’s history.